By John M. Kirkwood MD, Michael T. Lotze MD, Joyce M. Yasko PhD (auth.)

Current melanoma Therapeutics, Fourth variation, written through greater than 60 well known authors, offers an insightful advisor to the overpowering inflow of information on an array of melanoma kinds, in addition to protocols for therapy and supportive care. Divided into 4 easy-to-read sections; healthcare execs can simply locate key info on pharmacokinetics, drug symptoms, and toxicities, plus concise summaries of epidemiology and accomplished administration counsel for issues similar to hematological, neurological, and cardiopulmonary toxicities. state of the art info, paired with quite a few professionally ready tables and charts, makes this an extraordinary source for all healthcare execs operating with this complicated disease.

Show description

Read Online or Download Current Cancer Therapeutics PDF

Best cancer books

How To Kill Cancer Cells: Make Your Body Healthy Now

Natalie Mitchell’s Amazon most sensible vendor moment publication “How To Kill melanoma Cells” units out transparent guidance for readers to create a physically surroundings within which melanoma cells can't thrive. every person has melanoma cells and with the clinical know-how to be had these days medical professionals can merely diagnose melanoma affliction while humans have already got built BILLIONS of energetic melanoma cells of their physique.

Cancer Incidence in Five Continents: Volume IX (IARC Scientific Publication No. 160)

It really is tricky to estimate the variety of humans around the globe who paintings diligently to assemble the information which are provided in melanoma occurrence in 5 Continents. something is apparent: it's a huge quantity. Their mixed paintings is summarized within the pages of this quantity. melanoma occurrence in 5 Continents has develop into the famous reference resource at the occurrence of melanoma in populations all over the world.

Cancer Caregiving in the United States: Research, Practice, Policy

Regardless of advances in detection and therapy, melanoma continues to be a resource of discomfort and misery to sufferers and of complicated demanding situations to the household taking care of them. the fashion towards shorter health center remains particularly has elevated the actual, mental, and fiscal burden on caregivers, frequently resulting in hostile results on sufferers.

Additional resources for Current Cancer Therapeutics

Example text

Recently, several studies have investigated the value of thiotepa in high doses to treat several tumor types such as chronic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, breast and ovarian carcinoma, and melanoma. DOSAGE AND ADMINISTRATION Thiotepa can be administered by several different routes including IV, intrapleural, intraperitoneal, intrapericardial, intratumor, intramuscular, intrathecal, and ophthalmic instillation. -. ~·~ •. 7 Ukg; it is not known whether thiotepa distributes into breast milk; Metabolism: extensively metabolized in the liver; primary active metabolite is trimethylene phosphoramide (TEPA); this metabolite may possess more potent cytotoxic activity than thiotepa; other metabolites may exist but are undefined at this time; Excretion: exhibits a biexponential half-life, with an alpha half-life of approximately 10 min and a beta half-life of about 125 min; total clearance ranges from 150-500 mUh/kg depending on the dose and patient parameters; approximately 60% of the IV dose is excreted in the urine within 24-72 h; TEPA excretion is slower than thiotepa DRUG INTERACTIONS The concomitant use of thiotepa and succinylcholine may cause prolonged respirations and apnea; thiotepa inhibits the activity of pseudocholinesterase, the enzyme that deactivates succinylcholine; in theory, thiotepa may inhibit the metabolism of other drugs; however, this has not been extensively evaluated in humans RESPONSE RATES SPECIAL PRECAUTIONS Avoid in patients who have experienced hypersensitivity reactions to the drug; all cytotoxic drugs may be embryotoxic or teratogenic; use with caution in pregnant or nursing patients {Continued on next page} Complete responses of38% and partial responses of 24% have been reported in patients with superficial bladder tumors; recurrence rates decrease when thiotepa is used in combination with rumor resection or fulguration; when used as palliative treatment in breast and ovarian carcinomas and in high-dose therapy regimens, response rates of20%-30% and 30%-50%, respectively, have been reported (Continued on next page) The information he re is provided as guidance only.

Caution with other bone marrow depressants and live virus vaccines I· RESPONSE RATES 1. ====~:·;,;_q: Avoid use of aspirin and nonsteroidal antiinflammatory agents; oral dose r- ~~~ TOXICITIES Hematologic: bone marrow suppression, leukopenia, thrombocytopenia, and h emolytic anemia are most common; leukocyte and platelet nadirs usually occur 2-3 wk posttreatment with recovery in 4-5 wk; irreversible bone marrow failure has been reported; Gl: nausea, vomiting, diarrhea, oral ulceration (d ose-dependent, common with high- dose regimens), esophagitis; Dennatologic: s~n hypersensitivity, allergic reaction hyperpigmentation; Pulmonary: pulmonary fibrosis, interstitial pneumonitis; Renal: proteinuria, elevated SGT and BUN; Miscellaneous: vasculitis, fever, chill, cough , hoarseness, alopecia, hematuria ..

7% response rate has been shown in brain metastases of non-small cell lung cancer; studies are ongoing in this patient population combining cisplatin and fotemustine; only 7% partial response has been reported with colorectal cancer TOXICITIES Hematologic: grade Ill and IV reversible leukopenia, thrombocytopenia, and anemia have been observed at several doses; no aplasia-related d~aths have been reported; Gl: mild nausea, vomiting, and epigastric pain; abnormal liver function tests have been noted in 22% of treated patients but no hepatotoxicity h as been observed; CNS: CNS toxicity has been reported with intraarterial administration; mild to severe ocular pain during the infusion, depending on the dose; severe loss of vision, blindness, and enceph alopathyrelated neurotoxicity have been observed with intraarterial administration; Miscellaneous: rare allergic reaction {fever and rash) during the infusion; rare supravenous hyperpigmentation PATIENT MONITORING .

Download PDF sample

Current Cancer Therapeutics by John M. Kirkwood MD, Michael T. Lotze MD, Joyce M. Yasko PhD
Rated 4.12 of 5 – based on 36 votes